Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05637697 · ClinicalTrials.gov registry record
Angelman Syndrome Video Assessment (ASVA) Source Material Study
A clinical trial, sponsored by The Emmes Company.
- Completed
- Registry status
- 73
- Enrollment target
NCT05637697: Completed study, sponsored by The Emmes Company.
NCT05637697 is a clinical trial that has completed, run by The Emmes Company. The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05637697 has completed, sponsored by The Emmes Company.
- COMPLETED
- Registry status
- 73 participants
- Enrollment target
Study Summary
This is a longitudinal, observational, nonrandomized, fully remote study enrolling approximately 55 participant-caregiver dyads. The study includes no treatments or interventions, and participants will not be asked to change their current treatments. The objective of this study is to gather sufficient source material videos to develop a scoring system for ASVA and to perform preliminary validation of that scoring system.
Primary Outcome
The objective of this study is to gather sufficient source material videos to develop a scoring system for ASVA and to perform preliminary validation of that scoring system.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-08-31 |
| Est. Completion | 2023-08-01 |
What the finished NCT05637697 record still lists
NCT05637697 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 73 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05637697 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05637697 about?
NCT05637697 is a clinical study titled "Angelman Syndrome Video Assessment (ASVA) Source Material Study". This is a longitudinal, observational, nonrandomized, fully remote study enrolling approximately 55 participant-caregiver dyads. The study includes no treatments or interventions, and participants will not be asked to change their current treatments. The objective of this study is to gather sufficie...
What is the current status of trial NCT05637697?
This trial is currently completed. The enrollment target is 73 participants. The study started on 2021-08-31. Estimated completion is 2023-08-01.
Who is sponsoring clinical trial NCT05637697?
This trial is sponsored by The Emmes Company, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI